Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).
Alessia MennittoEmma ZattarinMassimo Di MaioDavide BimbattiUgo De GiorgiSebastiano ButiDaniele SantiniChiara CasadeiMariella SorarùCarlo MessinaClaudia MucciariniGiuseppe Di LorenzoGiandomenico RovielloConsuelo ButtiglieroMarco StellatoPierangela SepeMelanie ClapsValentina GuadalupiArianna OttiniSandro PignataFilippo G De BraudElena VerzoniGiuseppe ProcopioPublished in: Expert review of anticancer therapy (2021)
We observed longer PPS in patients continuing cabozantinib beyond PD, suggesting that this could be an effective option.